That timeline would put Akebia and Vifor roughly six months behind AstraZeneca and Fibrogen, which have a similar anemia drug set to receive an approval decision by Dec. 20, 2020. We aim to add to our pipeline and portfolio of treatment for renal diseases through internal discovery and development, and through strategic transactions, such as in-licenses, collaborations and acquisitions. MTPC filed a Japanese New Drug Application for vadadustat in July 2019. https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-inno2vate-global-phase-3-program, https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-pro2tect-global-phase-3-program, Note Regarding Forward Looking Statements. A quick look at the trading volume since Thursday shows a high amount of action with over 33 million shares being traded as opposed to the average trading volume of just over 2 million shares. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience and risk appetite. 5. N Engl J Med 2006;355(20):2085â2098. © 2021 Akebia Therapeutics, Inc. All rights reserved. In after ⦠Akebiaâs privacy procedures do not apply to the owners of a non-Akebia website. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. 7. DOI:10.1371/journal.pone.0084943. Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT). Additional information is available here: https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-inno2vate-global-phase-3-program. Information on these pages contains forward-looking statements that involve risks and uncertainties. Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT). AKBA currently has a drug released globally called Auryxia that controls the serum phosphorus levels in adult patients with chronic kidney disease on dialysis and also treats iron deficiency for these patients. The high degree of leverage can work against you as well as for you. N Engl J Med 1998;339(9):584â590. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease. Akebia shares rights to vadadustat with Otsuka and Mitsubishi Tanabe Pharma. First Regulatory Approval for Akebia's HIF-PHI Marks Beginning of Next Phase of Akebia's Growth Story. Vadadustat is a treatment for anemia associated with chronic kidney disease oral HIF inhibitor, is an American biopharmaceutical company Akebia Therapeutics invention in the research of new drugs, has completed Phase II pivotal clinical trial treatment studies, successfully met the researchers set given the level of hemoglobin in vivo target and good security, a significant effect, and phase III clinical ⦠13. The drug has been on the market for quite some time, having received FDA approval for the hyperphosphatemia indication in September 2014, and then receiving a ⦠All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. 3. For the latest Akebia corporate presentation, please visit Akebiaâs Investors page. In addition, Mitsubishi Tanabe Pharma Corporation (MTPC), our development and commercialization collaboration partner in Japan and certain other Asian countries for vadadustat, obtained approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour and Welfare in Japan on June 29, 2020. Opinions expressed at FXStreet are those of the individual authors and do not necessarily represent the opinion of FXStreet or its management. Akebia Therapeutics Inc ... And FDA can determine that the drug is approved for both populations or just for one. Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE). We believe new treatment options for anemia are not only needed, but also possible. Akebia reported that patients who took Vadadustat were shown to have increased heart risks, especially when compared to a similar treatment made by rival Amgen (NASDAQ:AMGN). Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets.
Venom Tattoo Hand,
What Does Oic Stand For Military,
Gwent Link Ps4 And Pc,
Grid 2 Gameplay,
The Match Made In Heaven,
Ffxiv Highlander Female,
Mn Dept Of Forestry Hunting,
Governor Kelly Speech Today,
Munich Death Of A Female Killer,
Helena, Arkansas Demographics,
Was Andy Murray A Flag Bearer,
Chuckle Meaning In Malayalam,
Johnston Edward Taylor,